Compare SIEB & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SIEB | AGEN |
|---|---|---|
| Founded | 1886 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.1M | 147.4M |
| IPO Year | 1996 | 1999 |
| Metric | SIEB | AGEN |
|---|---|---|
| Price | $1.83 | $3.46 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 16.6K | ★ 889.8K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | 0.13 | ★ 1.02 |
| Revenue | ★ $94,202,000.00 | $42,877,086.00 |
| Revenue This Year | N/A | $107.63 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.85 | ★ $3.48 |
| Revenue Growth | 12.28 | ★ 89.95 |
| 52 Week Low | $1.68 | $2.71 |
| 52 Week High | $5.53 | $7.34 |
| Indicator | SIEB | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 44.34 | 42.58 |
| Support Level | $1.68 | $2.91 |
| Resistance Level | $1.97 | $4.72 |
| Average True Range (ATR) | 0.08 | 0.25 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 25.08 | 22.43 |
Siebert Financial Corp is a diversified financial services firm and provides a full range of brokerage and financial advisory services including securities brokerage, investment advisory and insurance offerings, and corporate stock plan administration solutions. The firm mainly provides online and traditional brokerage and related services to retail investors and also acts as an investment advisor for its subsidiary. The company operates in the securities brokerage and asset management industry. It also engages in Insurance services, Robo-advisory technology, and Prime brokerage business through its subsidiaries.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.